Yoshihara Hiroki, Kamiya Takahiro, Hosoya Yosuke, Hasegawa Daisuke, Ogawa Chitose, Asanuma Hiroshi, Mizuno Ryuichi, Hosoya Ryota, Manabe Atsushi
Department of Pediatrics, St Luke's International Hospital, Tokyo, Japan.
Department of Urology, Keio University School of Medicine, Tokyo, Japan.
Pediatr Int. 2016 Aug;58(8):766-9. doi: 10.1111/ped.12963. Epub 2016 Jun 21.
Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) of the kidney is extremely rare, and is usually diagnosed after nephrectomy without neoadjuvant chemotherapy. Although ifosfamide and etoposide improve survival to a great extent in ES/PNET, the use of nephrotoxic agent, particularly ifosfamide, is a concern after nephrectomy. We describe the case of a 14-year-old female patient with abdominal mass who was diagnosed with ES/PNET of the right kidney after nephrectomy. Adjuvant chemotherapy including ifosfamide and etoposide were given. The estimated glomerular filtration rate decreased to 75% after the end of therapy. There was no evidence of recurrence 70 months after initial diagnosis.
肾脏尤因肉瘤/原始神经外胚层肿瘤（ES/PNET）极为罕见，通常在未进行新辅助化疗的肾切除术后才得以诊断。尽管异环磷酰胺和依托泊苷在很大程度上提高了ES/PNET患者的生存率，但肾切除术后使用肾毒性药物，尤其是异环磷酰胺，仍是一个令人担忧的问题。我们报告一例14岁女性腹部肿块患者，肾切除术后被诊断为右肾ES/PNET。给予了包括异环磷酰胺和依托泊苷在内的辅助化疗。治疗结束后，估计肾小球滤过率降至75%。初次诊断70个月后无复发迹象。
